跳至主要内容
临床试验/NCT03732339
NCT03732339已完成不适用

Predictive Value of Circulating Tumor Cells in Neoadjuvant Chemotherapy Among Locally Advanced Breast Cancer Patients: a Single-center, Prospective, Exploratory Clinical Trial

RenJi Hospital1 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2018年8月24日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
29
试验地点
1
主要终点
Predictive value of CTC in ypT0 ypN0

研究概览

简要总结

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. The purpose of this clinical trial is to evaluate the predictive value of CTC in neoadjuvant chemotherapy among locally advanced breast cancer patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients with histologically confirmed primary invasive breast adenocarcinoma, anatomic stage T2-4N0-3M0 or T1N1-3M0 before neoadjuvant chemotherapy
  • Adequate organ function
  • Consent to undergo CTC analysis in vivo

排除标准

  • Pregnant or breastfeeding patients
  • Metastatic or recurrent patients
  • Uncontrollable infection

结局指标

主要结局

Predictive value of CTC in ypT0 ypN0

时间窗: Change from pre-chemotherapy to 22-28(±7) days after first dose of neoadjuvant chemotherapy

次要结局

  • Detection rate of GILUPI CellCollector®(before and 22-28(±7) days after first dose of neoadjuvant chemotherapy)
  • Predictive value of CTC in ypT0, ypT0/is ypN0, near pCR(before and 22-28(±7) days after first dose of neoadjuvant chemotherapy)
  • hypersensitivity(up to 1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jinsong Lu

Chief of Breast Surgery Department

RenJi Hospital

研究点 (1)

Loading locations...

相似试验